Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Communicable Diseases Agency
Press Releases

HPV9 vaccine added to national immunisation schedules from January 2027

2 October 2026

  1. From 1 January 2027, eligible Singaporean and Permanent Resident females will have access to broader protection against cervical cancer, with the addition of the human papillomavirus 9-valent (HPV9) vaccine to the National Childhood Immunisation Schedule (NCIS), National Adult Immunisation Schedule (NAIS), and Subsidised Vaccine List (SVL). 

  2. HPV vaccination is recommended for females aged 9 to 26 for the prevention of cervical cancer. The HPV9 vaccine, also known as Gardasil 9, will be included in the NCIS and NAIS for females aged 9 to 26. The HPV2 vaccine, also known as Cervarix, will remain on both schedules as an alternative option. 

  3. Both the HPV2 and HPV9 vaccines protect against HPV types 16 and 18, which cause 70% of all cervical cancers. The HPV9 vaccine provides broader protection by also covering additional HPV types that account for a further 20% of cervical cancers, bringing its total coverage to approximately 90%.  

Updated Recommendations from the Expert Committee on Immunisation 

  1. The Expert Committee on Immunisation (ECI) has updated the HPV vaccination recommendations under the NCIS and NAIS, as follows: 

    1. Unvaccinated females may start or complete their vaccination series with either the HPV2 or HPV9 vaccine. For females receiving their first dose at age 9 to 14, two doses are recommended. For females receiving their first dose at age 15 to 26, three doses are recommended. If HPV vaccination is initiated but not completed by age 26, the remaining doses may be completed after age 26, as early as possible, but up to age 45.  

    2. Females who have started their vaccination series with the HPV2 or HPV41 vaccine and who are pending further doses may complete their vaccination series by receiving the HPV9 vaccine.  Studies have shown that such mixed HPV vaccination schedules are safe and provide protection against the HPV strains covered by both vaccines. 

    3. For individuals who have completed their recommended HPV vaccination schedule with the HPV2, HPV4, or HPV9 vaccines, the ECI does not recommend that they receive additional HPV9 vaccine doses.  

  2. Individuals may wish to consult their doctor on their HPV vaccination needs and recommended schedule. 

Changes to the National School-Based HPV Vaccination Programme 

  1. From 1 January 2027, the HPV9 vaccine will replace the HPV2 vaccine for female students who have yet to start or complete their vaccination series under the Health Promotion Board (HPB)’s school-based HPV vaccination programme. Under the programme, HPV vaccinations are currently provided to Secondary 1 and 2 female students at no charge.  

  2. Female students who have received the HPV2 vaccine as the first dose in 2026 (i.e. the 2026 Secondary 1 cohort) will be scheduled to complete their series in schools in 2027 with the HPV9 vaccine as the second dose.   

  3. In line with the ECI recommendations, female students who have completed their HPV vaccination series are not eligible for further HPV9 doses under the school-based HPV vaccination programme. 

Subsidies and MediSave 

  1. From 1 January 2027, eligible Singaporean children will receive full subsidies for the HPV9 vaccine at CHAS GP clinics and polyclinics, while eligible Singaporean adults can receive means-tested subsidies of up to 75% at these settings. Eligible Permanent Residents can receive subsidies at polyclinics. 

  2. MediSave use for the HPV9 vaccine will also be extended to those in the recommended groups under the NCIS and NAIS from 1 January 2027 up to MediSave Chronic and Preventive Care limits of $700 or $1,0002. Vaccination subsidies and MediSave use will not be applicable to additional doses of the HPV9 vaccine administered to individuals who have already completed the recommended doses. 

  3. Eligible individuals can book HPV vaccination appointments at participating CHAS GP clinics through https://vaccine.gov.sg (opens in new tab) or make an appointment at polyclinics. Vaccination with the HPV9 vaccine will be available from 1 January 2027. Healthier SG enrollees3 are encouraged to book their vaccination appointment at their enrolled clinic.

  4. Please visit the Ministry of Health website on the updated SVL, and the Communicable Diseases Agency website for more information on the updated NCIS and NAIS, including the full vaccination schedules and recommendations. 

MINISTRY OF HEALTH

COMMUNICABLE DISEASES AGENCY

HEALTH PROMOTION BOARD

2 OCTOBER 2026

1 HPV4 (previously known as Gardasil) is no longer available in Singapore and has been removed from the NCIS and NAIS. 

2 Patients who have received treatment within a calendar year for either two or more different Chronic Disease Management Programme (CDMP) conditions, or for at least one CDMP condition with recognised complications, will be eligible to use up to $1,000. 

3 For those who initiate HPV vaccination but did not complete it by age 26, may continue and complete the remaining doses after age 26 ideally as soon as possible and up to age 45.